Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of euphorbia factor l2 in preparation of medicine for treating acute lung injury

A technology for acute lung injury and euphorbia factor, which is applied in drug combination, antipyretics, and pharmaceutical formulations, and can solve problems such as the absence of euphorbia factor L2

Active Publication Date: 2021-01-08
WEST CHINA HOSPITAL SICHUAN UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no research on Euphorbia factor L2 as an anti-inflammatory drug in animal disease models or clinical application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of euphorbia factor l2 in preparation of medicine for treating acute lung injury
  • Application of euphorbia factor l2 in preparation of medicine for treating acute lung injury
  • Application of euphorbia factor l2 in preparation of medicine for treating acute lung injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1: Pharmacodynamic study of euphorbia factor L2 in the treatment of acute lung injury

[0024] 1. Experimental method

[0025] Thirty-six 8-week-old male C57BL / 6N mice were randomly divided into three groups: the control group, the model group, and the Euphorbia factor L2 treatment group (intraperitoneal injection, 40 mg / kg, administered 2 hours before modeling). They were anesthetized with ketamine (125 mg / kg) and xylazine (8 mg / kg), and 40 μl of sterile PBS or LPS (1 mg / ml, E.coli0111:B4, sigma) were instilled into the trachea, respectively, and the incision was then sutured. The survival rate of mice within 24 h was recorded. After 24 hours, the mice were sacrificed to obtain the lungs, which were fixed and embedded in 4% formaldehyde. The lung tissue was sectioned after dewaxing and dehydration, and hematoxylin-eosin (Hematoxylin-Eosin, HE) was used for pathological analysis. After 24 hours, bronchial alveolar lavage fluid (BALF) was collected and centrif...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses separation and preparation of a euphorbia factor L2 and a novel application of the euphorbia factor L2 to treatment of acute lung injury. The euphorbia factor L2 is a diterpeneester compound extracted and separated from semen euphorbiae lathyridis serving as a traditional Chinese medicinal material and displays good treatment effects on a lipopolysaccharide induced acute lung injury mouse model, and the euphorbia factor L2 has exact functions of resisting inflammatory diseases such as the acute lung injury and can be combined with auxiliary materials to prepare a medicine for resisting the inflammatory diseases such as the acute lung injury of a respiratory system or combined with other medicines for treating the acute lung injury in application.

Description

technical field [0001] The invention relates to the application of euphorbia factor L2, an active component of the traditional Chinese medicine Stephania chinensis, in the preparation of medicines for treating acute lung injury, and belongs to the field of traditional Chinese medicines. Background technique [0002] Acute lung injury (ALI) is an acute and progressive alveolar epithelial cell and capillary endothelial cell injury process caused by a variety of direct and indirect pathogenic factors, which can cause diffuse pulmonary interstitial and alveolar edema, causing acute lung injury. Hypoxic respiratory insufficiency. The main pathological features of ALI are decreased lung volume, decreased lung compliance, and imbalance of ventilation / perfusion flow ratio, clinically manifested as progressive hypoxemia and respiratory distress, and lung imaging showed heterogeneous exudation Lesions, which develop to a severe stage (oxygenation index <200) are called acute respi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/235A61P29/00A61P11/00A61P11/06
CPCA61K31/235A61K36/47
Inventor 罗玉斌成小兰鲁晨阳王琦陶伟伟刘毅
Owner WEST CHINA HOSPITAL SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com